Jiangsu Hengrui Medicine Co Ltd - Company Profile
Powered by 
All the data and insights you need on Jiangsu Hengrui Medicine Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Jiangsu Hengrui Medicine Co Ltd Strategy Report
- Understand Jiangsu Hengrui Medicine Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View up-to-date information on Jiangsu Hengrui Medicine Co Ltd patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| EP3907218A4 | Search Report | 6-OXO-1,6-DIHYDROPYRIDAZINDERIVAT, HERSTELLUNGSVERFAHREN DAFÜR UND MEDIZINISCHE ANWENDUNG DAVON | A61K31/50; A61P25/00; A61P29/00; C07D237/20; C07D237/22 | September 21, 2022 |
| EP3981787A4 | Search Report | ANTIKÖRPER GEGEN DEN BINDEGEWEBEWACHSTUMSFAKTOR UND SEINE VERWENDUNG | A61K2039/505; A61P1/16; A61P11/00; A61P13/12; A61P17/00; A61P19/02; A61P27/06; A61P3/10; A61P35/00; A61P9/10; A61P9/12; C07K16/22; C07K2317/20; C07K2317/24; C07K2317/33; C07K2317/73; C07K2317/76; C07K2317/92; C12N15/63; G01N2333/71; G01N33/6872 | September 14, 2022 |
| WO2022184114A1 | Application | METHOD FOR TREATING AUTOIMMUNE DISEASES AND INFLAMMATIONS WITH ANTI-IL-17 ANTIBODY | September 09, 2022 | |
| AU2021223128A1 | Application | Pharmaceutical composition containing anti-IL-4R antibody and use thereof | A61K39/395; A61K47/26; A61P11/06; C07K16/28 | September 08, 2022 |
| US20220280536A1 | Application | PHARMACEUTICAL COMPOSITION | A61K31/58; A61K9/0053; A61K9/1694; A61K9/2013; A61K9/2018; A61K9/2027; A61K9/2054 | September 08, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer